From microbial upcycling to biology-oriented synthesis: combining whole-cell production and chemo-enzymatic functionalization for sustainable taxanoid delivery von Hirte, M, Mischko, W, Kemper, K, Röhrer, S, Huber, C, Fuchs, M, Eisenreich, W, Minceva, M, Brück, T. B

Volltext

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial von Oza, Amit M, Prof, Cibula, David, Prof, Benzaquen, Ana Oaknin, MD, Poole, Christopher, Prof, Mathijssen, Ron H J, Prof, Sonke, Gabe S, MD, Colombo, Nicoletta, MD, Špaček, Jiří, MD, Vuylsteke, Peter, MD, Hirte, Holger, MD, Mahner, Sven, MD, Plante, Marie, MD, Schmalfeldt, Barbara, Prof, Mackay, Helen, MD, Rowbottom, Jacqui, PhD, Lowe, Elizabeth S, MD, Dougherty, Brian, PhD, Barrett, J Carl, PhD, Friedlander, Michael, Prof

Volltext

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomise... von Gelmon, Karen A, Prof, Tischkowitz, Marc, MD, Mackay, Helen, MD, Swenerton, Kenneth, MD, Robidoux, André, Prof, Tonkin, Katia, Prof, Hirte, Hal, MD, Huntsman, David, Prof, Clemons, Mark, MD, Gilks, Blake, Prof, Yerushalmi, Rinat, MD, Macpherson, Euan, MSc, Carmichael, James, MD, Oza, Amit, Prof

Volltext

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial von Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

Volltext

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled s... von Gotlieb, Walter H, Dr, Amant, Frederic, MD, Advani, Suresh, MD, Goswami, Chanchal, MD, Hirte, Hal, MD, Provencher, Diane, MD, Somani, Naresh, MD, Yamada, S Diane, MD, Tamby, Jean-Francois, MD, Vergote, Ignace, MD

Volltext

Variation of Electric Shielding on Virtual Frisch-Grid Detectors von Polack, J., Hirte, M, Sturgess, J, Sferrazza, N, Bolotnikov, A, Bablola, S, Camarda, G, Cui, Y, Egarievwe, S, et. al

Volltext

On the integration of a 2.4 GHz ISM band antenna in proximity to transmission lines von Ndip, I., Hirte, M., Guttowski, S., Reichl, H.

Volltext

Modeling and comparison of patch antenna configurations for 77 GHz radar applications von Ndip, I., Hirte, M., Guttowski, S., Reichl, H.

Volltext

Electrical modeling and analysis of the impact of slits on microstrip lines in thin film polymer layers von Ndip, I., Topper, M., Becker, K.-F., Hirte, M., Eidner, I., Fischer, T., Curran, B., Bauer, J., Scheel, W., Guttowski, S., Reichl, H.

Volltext bestellen

Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment von Poznanski, Sophie M, Singh, Kanwaldeep, Ritchie, Tyrah M, Aguiar, Jennifer A, Fan, Isabella Y, Portillo, Ana L, Rojas, Eduardo A, Vahedi, Fatemeh, El-Sayes, Abdullah, Xing, Sansi, Butcher, Martin, Lu, Yu, Doxey, Andrew C, Schertzer, Jonathan D, Hirte, Hal W, Ashkar, Ali A

Volltext

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced... von Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., Schwartz, B.

Volltext

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I von Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., Hirte, H., Konner, J.A., Lim, P.C., Prasad-Hayes, M., Monk, B.J., Pautier, P., Wang, J., Berkenblit, A., Vergote, I., Birrer, M.J.

Volltext

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) von Dhani, Neesha C, Hirte, Hal W, Wang, Lisa, Burnier, Julia V, Jain, Angela, Butler, Marcus O, Welch, Stephen, Fleming, Gini F, Hurteau, Jean, Matsuo, Koji, Matei, Daniela, Jimenez, Waldo, Johnston, Carolyn, Cristea, Mihaela, Tonkin, Katia, Ghatage, Prafull, Lheureux, Stephanie, Mehta, Anjali, Quintos, Judy, Tan, Qian, Kamel-Reid, Suzanne, Ludkovski, Olga, Tsao, Ming-Sound, Wright, John J, Oza, Amit M

Volltext

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors von McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K.N., Poveda, A., Hilpert, F., Hasegawa, K., Bacon, M., Gatsonis, C., Brand, A., Kridelka, F., Berek, J., Ottevanger, N., Levy, T., Silverberg, S., Kim, B.-G., Hirte, H., Okamoto, A., Stuart, G., Ochiai, K.

Volltext

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer von Oza, Amit M, Matulonis, Ursula A, Alvarez Secord, Angeles, Nemunaitis, John, Roman, Lynda D, Blagden, Sarah P, Banerjee, Susana, McGuire, William P, Ghamande, Sharad, Birrer, Michael J, Fleming, Gini F, Markham, Merry Jennifer, Hirte, Hal W, Provencher, Diane M, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah K, Schwartz, Benjamin, Braly, Patricia, Hall, Geoff D, Nephew, Kenneth P, Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

Volltext

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer von Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, Monk, Bradley J

Volltext

Telomerase Activity in Human Ovarian Carcinoma von COUNTER, C. M, HIRTE, H. W, BACCHETTI, S, HARLEY, C. B

Volltext

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors von Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.

Volltext

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas von Duran, I, Kortmansky, J, Singh, D, Hirte, H, Kocha, W, Goss, G, Le, L, Oza, A, Nicklee, T, Ho, J, Birle, D, Pond, G R, Arboine, D, Dancey, J, Aviel-Ronen, S, Tsao, M-S, Hedley, D, Siu, L L

Volltext

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) von Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J

Volltext